Evidence map›Paper›PMID 38073632›Full record

ArticleFrontiers in neurology2023

Case report and literature review: exploration of molecular therapeutic targets in recurrent malignant meningioma through comprehensive genetic analysis with Todai OncoPanel.

Kenta Ohara, Satoru Miyawaki, Hirofumi Nakatomi, Atsushi Okano, Yu Teranishi, Yuki Shinya, Daiichiro Ishigami, Hiroki Hongo, Shunsaku Takayanagi, Shota Tanaka and 9 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Kenta OharaDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Satoru MiyawakiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Hirofumi NakatomiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Atsushi OkanoDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Yu TeranishiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Yuki ShinyaDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Daiichiro IshigamiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroki HongoDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Shunsaku TakayanagiDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Shota TanakaDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Aya Shinozaki-UshikuDepartment of Pathology, The University of Tokyo Hospital, Tokyo, Japan.
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Hidenori KageDepartment of Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyoshi MiyagawaLaboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki AburataniGenome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Kenji TatsunoGenome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Nobuhito SaitoDepartment of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite accumulating research on the molecular characteristics of meningiomas, no definitive molecularly targeted therapy for these tumors has been established to date. Molecular mechanisms underlying meningioma progression also remain unclear. Comprehensive genetic testing approaches can reveal actionable gene aberrations in meningiomas. However, there is still limited information on whether profiling the molecular status of subsequent recurrent meningiomas could influence the choice of molecular-targeted therapies. Case presentation: We report a case of meningioma with malignant progression and multiple recurrences. We performed matched tumor pair analysis using the Todai OncoPanel to investigate the possibility of additional standard treatments. The loss of several chromosomal regions, including Conclusion: Gene panel testing platforms such as the Todai OncoPanel represent a powerful approach to elucidate actionable genetic alterations in various types of tumors, although their use is still limited to the diagnosis and prediction of prognosis in meningiomas. To enable targeted molecular therapy informed by gene-panel testing, further studies including matched tumor pair analyses are required to understand the molecular characteristics of meningiomas and develop treatments based on genetic abnormalities.

Indexed as

actionable gene aberrationcomprehensive genomic analysismalignant meningiomamalignant progressionTodai OncoPanel

Identifiers

PMID38073632
PMCPMC10702344
OpenAlexW4388946029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.